3sbio Sustainability Profile
3SBio Inc., a leading biopharmaceutical company headquartered in China, has established itself as a key player in the biotechnology industry since its founding in 1993. With a strong operational presence across major regions in Asia, 3SBio focuses on the development, manufacturing, and marketing of innovative therapies, particularly in the fields of oncology, nephrology, and autoimmune diseases. The company is renowned for its core products, including recombinant human erythropoietin and other biologics, which are distinguished by their high quality and efficacy. Over the years, 3SBio has achieved significant milestones, including successful product launches and strategic partnerships, solidifying its market position as a trusted provider of biopharmaceutical solutions. With a commitment to advancing healthcare, 3SBio continues to drive innovation and improve patient outcomes in the biopharmaceutical landscape.
DitchCarbon Score
How does 3sbio's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
3sbio's score of 24 is lower than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
3sbio's reported carbon emissions
In 2024, 3SBio reported total carbon emissions of approximately 69,136,120 kg CO2e, comprising 13,304,070 kg CO2e from Scope 1 and 55,832,050 kg CO2e from Scope 2 (market-based). In 2023, the company recorded total emissions of about 60,649,530 kg CO2e, with Scope 1 emissions at 11,663,450 kg CO2e and Scope 2 emissions at 48,986,080 kg CO2e (location-based). Over the years, 3SBio has shown a commitment to transparency in its emissions reporting, disclosing data for both Scope 1 and Scope 2 emissions, while not currently reporting on Scope 3 emissions. The company has not set specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). The emissions data is sourced directly from 3SBio Inc., with no cascading from a parent or related organization. The company continues to monitor its carbon footprint as part of its operational strategy, aligning with industry standards for climate accountability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 5,960,680 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 42,724,590 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - |
How Carbon Intensive is 3sbio's Industry?
How Carbon Intensive is 3sbio's Location?
3sbio's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
3sbio has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
